Brochure
18 Oct 2021

Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial

Summary
Background Bifidobacterium bifidum MIMBb75 is one of a few probiotic strains that have been shown to be effective inthe treatment of irritable bowel syndrome (IBS) and its symptoms. Non-viable strains might have advantages over viablebacteria for product stability and standardisation, as well as for tolerability because safety concerns have been raised forspecific patient groups who are susceptible to infection. We aimed to assess the efficacy of non-viable, heat-inactivated(HI) B bifidum MIMBb75 (SYN-HI-001) in the treatment of IBS and its symptoms.

Link: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(20)30056-X/fulltext

DOI: https://doi.org/10.1016/S2468-1253(20)30056-X

Content provided by our supplier

Synformulas GmbH

  • DE
  • 2021
    On CPHI since
  • 3
    Certificates
  • 100 - 249
    Employees
Company types
Manufacturer/Innovator

Other Content from Synformulas GmbH ()